The pecularities of the use of antiarrhythmic drugs in patients with cardiac comorbidities
Keywords:
antiarrhythmics, cardiac comorbidities, beta-adrenoblockers, amiodaroneAbstract
Cardiac arrhythmias constitute an emergency in cardiology due to the negative consequences on life prognosis. The most common causes of arrhythmias are cardiovascular comorbidities. It was determined that the most frequent comorbidity accompanying atrial fibrillation was arterial hypertension (95,23%), followed by heart failure (79,76%), ischemic, hypertrophic, mixed heart disease (77,38%) and angina pectoris (69,04%). The treatment of atrial fibrillation in patients with heart failure responded well to amiodarone, and in patients with hypertension and arrhythmia - to beta-adrenoblockers, drugs that inhibit the renin-angiotensin-aldosterone system. Amiodarone can be used safely in patients with left ventricular dysfunction after myocardial infarction, congestive heart failure, or hypertrophic cardiomyopathy. Beta-adrenoblockers have shown little effectiveness in patients with atrial fibrillation and heart failure.
References
1. Crivceanschii L.D. Urgenţe medicale. Ghid practic. Chişinău, 2011. Ediţia a IV-a.
2. Victor Botnaru. Boli cardiovasculare. Chisinau 2008, p.178.
3. Victor Ghicavîi V., Nicolae Bacinschi N., Gheorghe Gușuilă Gh. Farmacologie. Chișinău 2019, p.409.
4. Niță I. "Medicamentele beta-blocante", Medicamente. ro. 2017, aprilie
5. Ogunsua A.A., Shaikh A.Y., Mohamed Ahmed, Atrial Fibrillation and Hypertension: Mechanistic, Epidemiologic, and Treatment Parallels. J.Methodist Debakey Cardiovasc. 2015, 11(4): 228-234. https://doi.org/10.14797/mdcj-11-4-228
6. Camm A.J., Kirchhof P., Gregory Y.H. et al. Guidelines for the management of patients with atrial fibrilation. European Heart Journal. 2010, 31, 2369-2429.
7. DeLago A.J., Essa M., Ghajar A. et al. Incidence and Mortality Trends of Atrial Fibrillation/Atrial Flutter in the United States 1990 to 2017, The American Journal of Cardiology. 2021; 148 (1), 78-83. https://doi.org/10.1016/j.amjcard.2021.02.014
8. Kotecha D., Holmes J., Krum H. et al. Efficacy of beta-blockers in patients with heart failure plus atrial fibrillation: An individual-patient data metaanalysis. Lancet. 2014; ID: 25193873. https://doi.org/10.1016/S0140-6736(14)61373-8
9. Jakub Gumprecht J. , Magdalena Domek M., Gregory Y. H. et al. Invited review: hypertension and atrial fibrillation: epidemiology, pathophysiology, and implications for management Hum Hypertens. 2019 Dec; 33(12): 824-836. https://doi.org/10.1038/s41371-019-0279-7
10. Fung J.W.H., Cheuk M.Yu., Leo C.C. et al. Role of betablocker therapy in heart failure and atrial fibrillation. Electrophysiol Rev., 2003(3): 236-42. https://doi.org/10.1023/B:CEPR.0000012390.43937.2c
11. Pinto J.V. Jr , Ramani K.S., Kown N.M,, Gheorghiade M. Amiodarone therapy in chronic heart failure and myocardial infarction: a review of the mortality trials with special attention to STAT-CHF and the GESICA trials. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina Prog Cardiovasc Dis. 1997 Jul-Aug; 40(1): 85-93. https://doi.org/10.1016/S0033-0620(97)80025-4
12. Carlisle M.C. , Fudim M., DeVore A.D. et al. , Jonathan P Piccini Heart Failure and Atrial Fibrillation, Like Fire and Fury. JACC Heart Fail. 2019 Jun; 7(6): 447-456. https://doi.org/10.1016/j.jchf.2019.03.005
13. Walker M., Patel P. , Kwon O. et al. Atrial Fibrillation and Hypertension: "Quo Vadis", Curr Hypertens Rev, 2022;18(1):39-53. https://doi.org/10.2174/1573402118666220112122403
14. Mehra R. "Global public health problem of sudden cardiac death". Journal of electrocardiology. 2007. 40 (6 Suppl): S118-22. https://doi.org/10.1016/j.jelectrocard.2007.06.023
15. Mujović N. , Dobrev D. , Marinković M.et al. The role of amiodarone in contemporary management of complex cardiac arrhythmias, Pharmacol Res, 2020 Jan;151:104521. https://doi.org/10.1016/j.phrs.2019.104521
16. Z i m e t b a u m P. A m i o d a ro n e fo r A t r i a l Fibrillation. Engl J Med 2007; 356:935-941 https://doi.org/10.1056/NEJMct065916
17. Mareev Y. , Cleland J.G.F. Should β-blockers be used in patients with heart failure and atrial fibrillation? Clin Ther. 2015 Oct 1;37(10):2215-24. https://doi.org/10.1016/j.clinthera.2015.08.017
18. Zoni-Berisso M., Lercari F., Carazza T., Domenicucci S. "Epidemiology of atrial fibrillation: European perspective". Clinical epidemiology. 2014. 6: 213-20. https://doi.org/10.2147/CLEP.S47385
19. "Who Is at Risk for an Arrhythmia?". http://www.nhlbi. nih.gov/. 2011.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
